Special Funding Program: 'Preclinical Drug Development'

Applicants' Guidelines

A. Introduction

German Cancer Aid is launching a new call to support academic preclinical drug development. The objective of the programme is to establish a national centre or network for providing a drug development pipeline from screenings to validated agents. The call is open for development of either small compounds or biologicals.

The programme aims at experts from the fields of biology, medicinal/pharmaceutical chemistry, pharmacology and immunotherapy who are welcome to present their ideas.

Funding of up to a maximum of € 15 million is available for a period of up to 5 years. A maximum of three consortia could be considered. In this context, core activities are not to be held in all consortia. This can lead to a bundling of expertise. The German Cancer Aid reserves the right to examine the submitted applications for synergy and overlaps as part of the review process and, if necessary, to motivate the applicants to merge. This could be done in the context of a workshop before the final decision of the expert panel.

B. General Comments / Procedure

We wish to point out that applications are not accepted from members of profit-making organizations or pharmaceutical industry, from persons living and working outside of Germany or from persons not permitted to publish results in a generally accessible form.

Nevertheless, members of pharmaceutical industry can act as cooperation partners.

Application and evaluation procedure

The application and evaluation procedure will comprise three steps:

- Letter of intent (LOI) / brief project outlines have to be submitted no later than December 13th, 2021.
- The full applications should be submitted until May 5th, 2022 (1:00 pm).
- Based on the evaluation of the full applications by an international board of referees, applicants will be invited either to present their ideas orally to the board of referees ('hearings') or to participate in a so called 'think tank' workshop for pooling expertise and to react to potential overlap of ideas.

Note:

Contacting members of the reviewer committee in the context of the evaluation of the application, can be interpreted as an attempt to influence their decisions and will lead to termination of the evaluation process.

If you have any questions, please contact:
Dr. Simone Billig, 0228 / 72990-219, e-mail: billig@krebshilfe.de
C. Guideline for Letter of Intent / Brief Project Outlines

The LOI / Brief Project Outlines must be sent as a pdf per email to the following address:

**foerderung@krebshilfe.de** (one PDF document, not exceeding 10 MB).

**Subject: Special Funding Program: 'Preclinical Drug Development'**

Within two weeks of receipt of LOI / brief project outline by the offices of German Cancer Aid, the applicant will receive a written confirmation of receipt. If you fail to receive a confirmation of receipt, please send an e-mail to the Funding Department of the German Cancer Aid (foerderung@krebshilfe.de), giving the full project title and your telephone number.

1. Applicants
   The following information is needed for the lead applicant as well as all co-applicants and cooperation partners. Please give the name of the lead applicant, who is the speaker of the network and contact person for correspondence with Deutsche Krebshilfe first:
   - First name, surname, academic degree and full name of the institution at which the Lead applicant works
   - List of all co-applicants and the full name of their participating centers/institutions
   - List of all cooperation partners and the full name of their institutions/company
   - Full name of the member of the advisory board if already designated

2. Project title (not more than 160 characters, including commas and spaces)

3. Project Overview (one page)
   Please give a brief description of the project and consortium. Specify substance classes of targets and compounds, respectively, and the rationale behind.

   **The LOI / Project Outlines must be signed at least by the lead applicant.**